Month: March 2023

HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023. Mr. Green will present on Tuesday, March 21 at 9:45 AM ET. A live webcast of the presentation will be available here. The presentation will also be archived on the Investor Relations section of the Harvard Bioscience website for a limited period of time. Harvard Bioscience will also host virtual one-on-one meetings with investors on Tuesday, March 21, 2023. To register for the presentation or to schedule a one-on-one meeting, please visit www.key.com/lsmt. About Harvard Bioscience Harvard Bioscience, Inc. is a leading developer,...

Following a competitive solicitation process, Blink was awarded a contract to provide the US Postal Service Electric Vehicle Supply Equipment. Miami Beach, Fla., March 16, 2023 (GLOBE NEWSWIRE) — Blink Charging Co. (NASDAQ: BLNK) (“Blink” or the “Company”), a leading manufacturer, owner, operator and provider of electric vehicle (EV) charging equipment and services, announced it was awarded an IDIQ contract by the United States Postal Service (USPS) to sell up to 41,500 EV charging units to support EV charging infrastructure for the USPS as part of its vehicle electrification strategy. “We are honored to be selected by the US Postal Service to provide our reliable and advanced EV charging stations and ancillary network services for their growing fleet of electric vehicles and we applaud their efforts to modernize and make the move...

EV Meter Offers the only End-to-End Charging Solutions with Embedded Payments HERZLIYA, Israel, March 16, 2023 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq; TASE: NYAX), a global commerce enablement and payments platform designed to help merchants scale their business, today announced that EV Meter, an innovative electric vehicle charging business, powered by Nayax, will be launching their charging solutions in North America at the EV Charging Summit & Expo, taking place in Las Vegas at the Mirage Hotel this month. Mr. Shane Prebenda, Director of Sales & Strategy, is leading EV Meter’s product introduction in North America. With over a decade of experience in digitalizing entire industries, Shane is excited to leverage his deep technical expertise and strategic vision to propagate a greener future for businesses, municipalities...

Award recognizes NeuroStar for its significant contributions toward patient wellbeing MALVERN, Pa., March 16, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is named a recipient of Life Sciences Pennsylvania’s (LSPA) annual Patient Impact Award for 2022. “We are honored that Life Sciences Pennsylvania has identified NeuroStar as a recipient of the Patient Impact Award,” said Keith J. Sullivan, President and CEO of Neuronetics. “We take pride in positively impacting the lives of individuals suffering from depression and other mental health conditions. We believe they deserve a safe, effective, and non-invasive treatment option when traditional...

Highlights:Incannex plans to open multiple psychedelic-assisted psychotherapy clinics in Australia and overseas. First clinic will open in Melbourne in 2023, followed by rapid expansion based on development of sound operating model. Dr. Paul Liknaitzky, Professor Suresh Sundram and Sean O’Carroll to join the Board of Directors of a subsidiary company and take key roles within the venture. Incannex owned subsidiary is being led by long time Incannex director, Mr Peter Widdows. Advanced stage of negotiation on riverfront premises in Melbourne for first clinic. Incannex believes the market will mature into a multi-billion-dollar opportunity.MELBOURNE, Australia, March 16, 2023 (GLOBE NEWSWIRE) — Incannex Healthcare Ltd (Nasdaq: IXHL). (ASX: IHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal...

The WIN Consortium partners include leading companies and academic institutions such as Elbit Systems (Nasdaq: ESLT), CEVA (Nasdaq: CEVA), Ceragon Networks (Nasdaq: CRNT) and Ben Gurion University Mobilicom worked closely with the consortium partners to develop and test AI and machine learning (ML) in a 5G field test of device-to-device systems for applications including drones and drone security Other applications include autonomous vehicles and drones for industrial and defense needsShoham, Israel, March 16, 2023 (GLOBE NEWSWIRE) — Mobilicom Limited (Mobilicom or the Company) (Nasdaq: MOB, MOBBW, ASX: MOB) a provider of cybersecurity and robust solutions for drones and robotics, in conjunction with the Wireless Intelligent Networks (WIN) Consortium, today announced the successful demonstration of artificial intelligence (AI)...

Growing body of data supports Ampligen’s potential as both a prophylactic and an early-onset therapy against human Ebola virus disease outbreaks OCALA, Fla., March 16, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced a late-breaking presentation at the 36th International Conference on Antiviral Research (ICAR) detailing Ampligen’s mechanism of action in the treatment of Ebola virus disease (EVD). The presentation was given by Angela Corona, PhD, Department of Life and Environmental Sciences, University of Cagliari, Monserrato, Italy, and one of the published...

New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing’s role in shortening the diagnostic odyssey STAMFORD, Conn., March 16, 2023 (GLOBE NEWSWIRE) — GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, announced new research today at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting which demonstrates exome sequencing’s diagnostic advantages in shortening patients’ and families’ diagnostic odysseys when compared with chromosomal microarray (CMA). To determine whether exome sequencing is comparable to CMA with respect to copy number variant (CNV) yield, GeneDx compared the reported CNV results on over 8,000 probands who had CMA and exome sequencing between...